| First Author | Bi E | Year | 2018 |
| Journal | J Clin Invest | Volume | 128 |
| Issue | 11 | Pages | 4821-4831 |
| PubMed ID | 30277474 | Mgi Jnum | J:271230 |
| Mgi Id | MGI:6279475 | Doi | 10.1172/JCI121421 |
| Citation | Bi E, et al. (2018) E-cadherin expression on multiple myeloma cells activates tumor-promoting properties in plasmacytoid DCs. J Clin Invest 128(11):4821-4831 |
| abstractText | Plasmacytoid dendritic cells (pDCs) play a key role in antiviral responses by producing type-1 IFNs. However, recent studies showed that pDCs induce immune suppression and promote tumor growth in human ovarian cancer and myeloma. The molecular mechanisms underlying pDC acquisition of these properties are unknown. Here we show that human pDCs activated by CpG inhibited growth and induced apoptosis in myeloma cells via secreted IFN-alpha, but direct contact with myeloma cells converted pDCs into tumor-promoting cells by suppressing pDC IFN-alpha production. E-cadherin, expressed on both myeloma cells and pDCs, mediated these effects via a homophilic interaction - activation of E-cadherin signaling upregulated and activated TNFAIP3 to interact with TLR9, resulting in TLR9 ubiquitination and degradation, and inhibition of IFN-alpha production in pDCs. These findings were supported by an in vivo study in which pDC depletion induced tumor regression and better survival in the Vk*MYC myeloma mouse model. Furthermore, IFNAR1 expression level positively correlated to overall survival of patients with multiple myeloma (MM), and the IFN-alpha level in patient bone marrow was significantly lower than that in marrow of healthy individuals. This study reveals a novel mechanism underlying how MM tumors educate pDCs in their microenvironment and provides new targets for improving the treatment of MM. |
